{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:36:26Z","timestamp":1792784186362,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Kyowa Kirin Co., Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jdermsci.2020.06.005","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T16:06:19Z","timestamp":1592064379000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis"],"prefix":"10.1016","volume":"99","author":[{"given":"Hidemi","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetake","family":"Shimabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Kikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ootaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2020.06.005_bib0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2500\/aap.2012.33.3569","article-title":"Epidemiology of atopic dermatitis: a review","volume":"33","author":"DaVeiga","year":"2012","journal-title":"Allergy Asthma Proc."},{"issue":"131","key":"10.1016\/j.jdermsci.2020.06.005_bib0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children\u2019s Health","author":"Shaw","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0015","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2013.07.008","article-title":"Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation","volume":"132","author":"Schmitt","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cyto.2014.11.023","article-title":"New pathogenic and therapeutic paradigms in atopic dermatitis","volume":"73","author":"Malajian","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/1346-8138.13392","article-title":"Committee for guidelines for the management of atopic dermatitis of Japanese Dermatological Association. Clinical practice guidelines for the management of atopic dermatitis 2016","volume":"43","author":"Saeki","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0040","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0045","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0050","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2019.10.039","article-title":"The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature","volume":"82","author":"Pavel","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0055","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/jdv.14313","article-title":"Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis","volume":"31","author":"Papp","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","article-title":"Control of immunity by the TNFR-related molecule OX40 (CD134)","volume":"28","author":"Croft","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0070","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1172\/JCI34182","article-title":"OX40-OX40L interactions: a promising therapeutic target for allergic diseases?","volume":"117","author":"Wang","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/157339506775471884","article-title":"OX-40:OX40L Axis: emerging targets for immunotherapy of human disease","volume":"2","author":"Salek-Ardani","year":"2006","journal-title":"Current Immunol Rev"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00403-002-0363-6","article-title":"Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin","volume":"294","author":"Matsumura","year":"2003","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00005-008-0032-3","article-title":"Is it wise to target the late costimulatory molecule OX40 as a therapeutic target?","volume":"56","author":"Cavanagh","year":"2008","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0090","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3452","article-title":"The OX40 Axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0095","first-page":"121","article-title":"Guidelines for management of atopic dermatitis, 2016","volume":"126","author":"Japanese Dermatological Association","year":"2016","journal-title":"J. Dermatol. B"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2340\/00015555-2302","article-title":"Usefulness of rajka & langeland eczema severity score in clinical practice","volume":"96","author":"G\u00e5nemo","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0105","first-page":"27","article-title":"Serum TARC\/CCL 17 levels as a disease marker of atopic dermatitis","volume":"116","author":"Tamaki","year":"2006","journal-title":"J. Dermatol. B"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0110","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3388\/jspaci.19.744","article-title":"Clinical utility serum TARC\/CCL 17 for monitoring clinical course of atopic dermatitis in children","volume":"19","author":"Fujisawa","year":"2005","journal-title":"Jpn. J. Pediatr. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0130","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","article-title":"Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy","volume":"18","author":"Dillman","year":"1999","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0135","series-title":"Tafinlar\u00ae [package insert]","year":"2020"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","article-title":"Pre-existing antibody: biotherapeutic modality-based review","volume":"18","author":"Gorovits","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0145","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/ajt.15245","article-title":"Immune dysregulation and Th2 polarization are associated with atopic dermatitis in heart-transplant children: a delicate balance between risk of rejection or atopic symptoms","volume":"19","author":"L\u00f3pez-Abente","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0150","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40257-018-0370-9","article-title":"Dupilumab: a review in moderate-to-severe atopic dermatitis","volume":"19","author":"Frampton","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0160","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-immunol-032414-112123","article-title":"Interleukin-22: immunobiology and pathology","volume":"33","author":"Dudakov","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0170","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1346-8138.1990.tb01679.x","article-title":"Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis","volume":"17","author":"Mukai","year":"1990","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0175","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1398-9995.2004.00476.x","article-title":"Eosinophils and atopic dermatitis","volume":"59","author":"Simon","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0180","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5021\/ad.2012.24.4.406","article-title":"Effect of the pruritus on the quality of life: a preliminary study","volume":"24","author":"Erturk","year":"2012","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0185","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bjd.17710","article-title":"Utility of the pediatric allergic disease quality of life questionnaire for childhood eczema","volume":"181","author":"Hon","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2020.06.005_bib0195","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181120302012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181120302012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:51:07Z","timestamp":1760331067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181120302012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0923181120302012"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.06.005","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}